Insmed Incorporated ranks slightly below the peer group median, with strong growth and stability offset by weak valuation. Trend conditions have deteriorated, without yet reaching an extreme downside state.
Peer-relative scores, weakest to strongest
Insmed Incorporated develops and commercializes therapies for rare and serious diseases, focusing on niche pharmaceuticals. Its portfolio includes treatments such as BRINSUPRI® and ARIKAYCE®.
INSM is priced on short-term growth despite weak structural quality. With an operating margin of -41% and 68.5% annual volatility, the market is rewarding revenue momentum from niche drugs while discounting persistent weak profitability and extreme price swings. INSM depends on just a few specialized therapies, unlike diversified biopharma peers, which increases concentration risks in every quarterly report. The market prices INSM for continued upside, reflecting optimism in near-term growth rather than factoring in the durability of its business model or the underlying risks. A setback in BRINSUPRI® or ARIKAYCE® would likely trigger a sharp rerating.
Break down INSM's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.